PureTech's candidate drug, LYT-100, for treating lymphedema by reducing fibrosis and inflammation, began treatment for the first participants in its clinical trial
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
PureTech announced that itsclinicalstudy of LYT-100, a candidate drug for lymphedema and other fibrosis diseases, had begun treatment for the first participantsthe trial was designed to assess the safety, tolerability and pharmacodynamics (PK) characteristics of LYT-100 in healthy subjectsBabak Mehrara, of the memorial Sloan Kettering Cancer Center in, said the diseases resulted in "severe disabilities, but few meaningful treatment options, most of which use compression and physiotherapy to control swelling." LYT-100 aims to address lymphedema by reducing fibrosis and inflammation and restoring lymphatic function, and I believe it has great potential as a candidate therapy for lymphedemaTheevaluated drug is an oral small molecular candidate drug called deupirfenidone, which has shownpreclinicalanti-fibrosis and anti-inflammatory activitylymphedema is a chronic disease characterized by a build-up of lymphatic fluid and inflammation, fibrosis and fat deposition that causes severe swelling of the body (usually the arm or leg)currentlyThe FDAhas not approved a drug that treats lymphedema, a chronic condition that causes pain and is sexual, affecting about 1 million people in the United States alone, including about 500,000breast cancersurvivors
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
